Terms: = Head and neck cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
1040 results:
1. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
2. First-line treatment Patterns and Outcomes in Advanced Non-Small Cell Lung cancer in Sweden: A Population-based Real-world Study with Focus on Immunotherapy.
Wagenius G; Vikström A; Berglund A; Salomonsson S; Bencina G; Hu X; Chirovsky D; Brunnström H
Acta Oncol; 2024 Apr; 63():198-205. PubMed ID: 38643377
[TBL] [Abstract] [Full Text] [Related]
3. Single cell analysis unveils B cell-dominated immune subtypes in HNSCC for enhanced prognostic and therapeutic stratification.
Li K; Zhang C; Zhou R; Cheng M; Ling R; Xiong G; Ma J; Zhu Y; Chen S; Chen J; Chen D; Peng L
Int J Oral Sci; 2024 Apr; 16(1):29. PubMed ID: 38622125
[TBL] [Abstract] [Full Text] [Related]
4. Difference between Keratinized- and Non-Keratinized-Originating Epithelium in the Process of Immune Escape of Oral Squamous Cell Carcinoma.
Kitsukawa Y; Fukumoto C; Hyodo T; Komiyama Y; Shiraishi R; Koike A; Yagisawa S; Kunitomi Y; Hasegawa T; Kotani W; Ishida K; Wakui T; Kawamata H
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612630
[TBL] [Abstract] [Full Text] [Related]
5. Partial recovery of peripheral blood monocyte subsets in head and neck squamous cell carcinoma patients upon radio(chemo)therapy is associated with decreased plasma CXCL11.
Idel C; Fleckner J; Plötze-Martin K; Werner L; Rades D; Theodoraki MN; Hofmann L; Huber D; Leichtle A; Hoffmann TK; Bruchhage KL; Pries R
BMC Cancer; 2024 Apr; 24(1):459. PubMed ID: 38609887
[TBL] [Abstract] [Full Text] [Related]
6. [Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
[No Abstract] [Full Text] [Related]
7. Histologic and Genomic Analysis of Conjunctival SCC in African and American Cohorts Reveal UV Light and HPV Signatures and High Tumor Mutation Burden.
Gleber-Netto FO; Nagarajan P; Sagiv O; Pickering CR; Gross N; Ning J; Yeshi MM; Mitku Y; Tetzlaff MT; Esmaeli B
Invest Ophthalmol Vis Sci; 2024 Apr; 65(4):24. PubMed ID: 38597722
[TBL] [Abstract] [Full Text] [Related]
8. Pembrolizumab-based first-line treatment for pd-l1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A; Marinelli D; Romeo U; Messineo D; De Felice F; De Vincentiis M; Valentini V; Mezi S; Valentini F; Vivona L; Chiavassa A; Cerbelli B; Santini D; Bossi P; Polimeni A; Marchetti P; Botticelli A
BMC Cancer; 2024 Apr; 24(1):430. PubMed ID: 38589857
[TBL] [Abstract] [Full Text] [Related]
9. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Dang S; Li X; Liu H; Zhang S; Li W
Cancer Med; 2024 Apr; 13(7):e7119. PubMed ID: 38553943
[TBL] [Abstract] [Full Text] [Related]
10. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
[TBL] [Abstract] [Full Text] [Related]
11. Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis.
Ye D; Liang X; Chen X; Li Y
Sci Rep; 2024 Mar; 14(1):6807. PubMed ID: 38514766
[TBL] [Abstract] [Full Text] [Related]
12.
Cytryn SL; Pandit-Taskar N; Lumish MA; Maron SB; Gu P; Ku GY; Chou JF; Capanu M; Antoine A; Loegel D; Feder L; Philemond S; Lyashchenko SK; Lewis JS; Paroder V; Srivastava A; Tang LH; Schoder H; Janjigian YY
J Nucl Med; 2024 May; 65(5):722-727. PubMed ID: 38514081
[TBL] [Abstract] [Full Text] [Related]
13. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.
Jiang Y; Zheng Y; Zhang YW; Kong S; Dong J; Wang F; Ziman B; Gery S; Hao JJ; Zhou D; Zhou J; Ho AS; Sinha UK; Chen J; Zhang S; Yin C; Wei DD; Hazawa M; Pan H; Lu Z; Wei WQ; Wang MR; Koeffler HP; Lin DC; Jiang YY
Nat Commun; 2024 Mar; 15(1):2484. PubMed ID: 38509096
[TBL] [Abstract] [Full Text] [Related]
14. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
15. Immune checkpoint CD161/LLT1-associated immunological landscape and diagnostic value in oral squamous cell carcinoma.
Hu X; Dong Y; Xie S; Song Y; Yu C; He Y; Wang Z; Hu Q; Ni Y; Ding L
J Pathol Clin Res; 2024 Mar; 10(2):e353. PubMed ID: 38502058
[TBL] [Abstract] [Full Text] [Related]
16. Epstein-Barr Virus BRLF1 Induces pd-l1 Expression in Nasopharyngeal Carcinoma Cells.
Wu CC; Chen MS; Lee TY; Huang TS; Cho DY; Chen JY
Viral Immunol; 2024 Mar; 37(2):115-123. PubMed ID: 38498796
[TBL] [Abstract] [Full Text] [Related]
17. Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Qian T; Liu D; Cao G; Chen Z; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241231610. PubMed ID: 38497137
[TBL] [Abstract] [Full Text] [Related]
18. Genetic and molecular characterization of metabolic pathway-based clusters in esophageal squamous cell carcinoma.
Wang Z; Zhang Y; Yang X; Zhang T; Li Z; Zhong Y; Fang Y; Chong W; Chen H; Lu M
Sci Rep; 2024 Mar; 14(1):6200. PubMed ID: 38486026
[TBL] [Abstract] [Full Text] [Related]
19. Dual checkpoint T(h1)eamwork makes the anti-cancer dream work.
Dietl A; Ralser A; Pelka K
Immunity; 2024 Mar; 57(3):406-408. PubMed ID: 38479356
[TBL] [Abstract] [Full Text] [Related]
20. The Use of Immune Regulation in Treating head and neck Squamous Cell Carcinoma (HNSCC).
Wang CW; Biswas PK; Islam A; Chen MK; Chueh PJ
Cells; 2024 Feb; 13(5):. PubMed ID: 38474377
[TBL] [Abstract] [Full Text] [Related]
[Next]
